Finding 952063 (2022-004)

Material Weakness
Requirement
H
Questioned Costs
$1
Year
2022
Accepted
2024-03-12

AI Summary

  • Core Issue: The organization charged costs to a federal award outside the approved budget period, leading to compliance violations.
  • Impacted Requirements: Lack of internal controls resulted in approximately $30,300 in questioned costs due to improper billing for expenditures related to a different performance period.
  • Recommended Follow-Up: Implement independent review procedures for verifying grant period compliance and maintain documentation of these reviews for future audits.

Finding Text

#2022-004 - Major Federal Award Finding - Period of Performance Nature of Finding: Compliance Finding - Period of Performance and Material Weakness in Internal Controls over Compliance Criteria/Condition: A non-federal entity may charge only allowable costs incurred during the approved budget period of a federal award’s period of performance. The Organization did not have controls in place to verify that costs were being charged to the award in the correct period of performance. Questioned Costs: Approximately $30,300 Identification of How Questioned Costs Were Computed: A sample of 40 non-payroll expenditures totaling approximately $92,000 was selected from a population of approximately $488,000 of non-payroll expenditures. Of the invoices selected for testing of non-payroll expenditures charged to the major program, $7,258 was related to the year ended December 31, 2023 and was inappropriately charged to the grant during 2022. Questioned costs are estimated by projecting the error identified in the sample tested to the population of non-payroll expenditures of the Opioid STR program. Cause/Context: There are not proper controls in place to review invoices and assign them to the appropriate grant period. Seven expenditures out of forty non-payroll related expenditures tested for the grant were for contracted annual services or other costs that partially or entirely related to a separate performance period but was billed in its entirety to the current fiscal year. Effect: An overstatement of expenditures for the grant was reported in the current year. Reimbursement was sought for expenditures outside of the grant's period of performance. Recommendation: We recommend procedures be established for the independent review of the grant period of performance when recording transactions and preparing grant reimbursement requests. Evidence of this review should be documented and maintained. Views of Responsible Officials and Planned Corrective Actions: MARR will retain a CPA consultant to establish formal written policy documenting significant accounting procedures including but not limited to the independent review of the grant period of performance when recording transactions and preparing grant reimbursement requests. Evidence of the review to be documented and maintained according to the procedures to be implemented.

Categories

Questioned Costs Period of Performance Allowable Costs / Cost Principles Cash Management Material Weakness Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 375613 2022-004
    Material Weakness
  • 375614 2022-005
    Material Weakness
  • 375615 2022-006
    Material Weakness
  • 375616 2022-007
    Material Weakness
  • 375617 2022-008
    Material Weakness
  • 375618 2022-009
    Material Weakness
  • 375619 2022-010
    Material Weakness
  • 375620 2022-011
    Material Weakness
  • 375621 2022-004
    Material Weakness
  • 375622 2022-005
    Material Weakness
  • 375623 2022-006
    Material Weakness
  • 375624 2022-007
    Material Weakness
  • 375625 2022-008
    Material Weakness
  • 375626 2022-009
    Material Weakness
  • 375627 2022-010
    Material Weakness
  • 375628 2022-011
    Material Weakness
  • 952055 2022-004
    Material Weakness
  • 952056 2022-005
    Material Weakness
  • 952057 2022-006
    Material Weakness
  • 952058 2022-007
    Material Weakness
  • 952059 2022-008
    Material Weakness
  • 952060 2022-009
    Material Weakness
  • 952061 2022-010
    Material Weakness
  • 952062 2022-011
    Material Weakness
  • 952064 2022-005
    Material Weakness
  • 952065 2022-006
    Material Weakness
  • 952066 2022-007
    Material Weakness
  • 952067 2022-008
    Material Weakness
  • 952068 2022-009
    Material Weakness
  • 952069 2022-010
    Material Weakness
  • 952070 2022-011
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
93.788 Opioid Str $133,750
93.959 Block Grants for Prevention and Treatment of Substance Abuse $60,744